Last reviewed · How we verify

Cycloplegia — Treatment Landscape & Competitive Intelligence

Cycloplegia (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Cycloplegia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Cyclogyl CYCLOPENTOLATE Alcon Labs Inc cyclopentolate Muscarinic acetylcholine receptor M3 1974-01-01
scopolamin scopolamin University Hospital, Angers Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 1 drug in Cycloplegia
  2. Alcon Labs Inc · 1 drug in Cycloplegia
  3. University Hospital, Angers · 1 drug in Cycloplegia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Cycloplegia:

Cite this brief

Drug Landscape (2026). Cycloplegia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/cycloplegia. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing